Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 25;14(10):960.
doi: 10.3390/brainsci14100960.

Cerebrospinal Fluid Neurofilaments Light-Chain Differentiate Patients Affected by Alzheimer's Disease with Different Rate of Progression (RoP): A Preliminary Study

Affiliations

Cerebrospinal Fluid Neurofilaments Light-Chain Differentiate Patients Affected by Alzheimer's Disease with Different Rate of Progression (RoP): A Preliminary Study

Valeria Blandino et al. Brain Sci. .

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and a leading cause of dementia. One major challenge for clinicians is accurately assessing the rate of disease progression (RoP) early in the diagnostic process, which is crucial for patient management and clinical trial stratification. This study evaluated the role of cerebrospinal fluid biomarkers-Aβ42, t-Tau, pTau, Neurogranin (Ng), and Neurofilament light-chain (NF-L)-in predicting RoP at the time of AD diagnosis. We included 56 AD patients and monitored cognitive impairment using MMSE scores at diagnosis and during six-month follow-up visits. RoP scores were calculated based on these assessments. Our correlation analyses revealed significant associations between RoP and pTau, Aβ42/Ng ratio, and NF-L levels. When patients were stratified by median RoP values into low-to-moderate (L-M: <2) and upper-moderate (U-M: >2) groups, those in the U-M group had notably higher CSF NF-L levels compared to the L-M group. Logistic regression analysis further demonstrated that elevated CSF NF-L levels were predictive of a faster RoP. These findings highlight the potential of CSF NF-L as a prognostic biomarker for rapid disease progression in AD. By identifying patients at risk for accelerated cognitive decline, CSF NF-L could significantly enhance early intervention strategies and improve patient management in clinical settings.

Keywords: Alzheimer’s disease; CSF; biomarkers; dementia; neurofilaments; progression.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Box plots representing CSF levels of (a) Aβ 1–42, (b) Aβ 42/40 ratio, (c) tTau, (d) pTau, (e) Ng, and (f) NF-L in AD patients stratified on the basis of the median value of RoP (i.e., L-M and U-M). * indicates a statistical significance with a p-value < 0.05.
Figure 2
Figure 2
ROC curve analysis of NF-L, with cut-off value, sensitivity, and specificity, calculated according to Youden’s index.

Similar articles

References

    1. Paroni G., Bisceglia P., Seripa D. Understanding the Amyloid Hypothesis in Alzheimer’s Disease. J. Alzheimer’s Dis. 2019;68:493–510. doi: 10.3233/JAD-180802. - DOI - PubMed
    1. Hardy J.A., Higgins G.A., Hardy J.A., Higgins G.A. Alzheimer’s: The Amyloid Cascade Hypothesis. Science. 1992;256:184–185. doi: 10.1126/science.1566067. - DOI - PubMed
    1. Selkoe D.J., Hardy J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years Dennis. EMBO Mol. Med. 2016;8:595–608. doi: 10.15252/emmm.201606210. - DOI - PMC - PubMed
    1. Lane C.A., Hardy J., Schott J.M. Alzheimer’s Disease. Eur. J. Neurol. 2018;25:59–70. doi: 10.1111/ene.13439. - DOI - PubMed
    1. Mauskopf J., Racketa J., Sherrill E. Alzheimer’s Disease: The Strength of Association of Costs with Different Measures of Disease Severity. J. Nutr. Health Aging. 2010;14:655–663. doi: 10.1007/s12603-010-0312-6. - DOI - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources

  NODES
Association 2
twitter 2